selected scholarly activity
-
books
- Preface. Ed. 1869. 2019
-
chapters
- Cancer Stem Cells: Current Challenges and Future Perspectives. Methods in molecular biology (Clifton, N.J.). 1-18. 2024
- Childhood Medulloblastoma: An Overview. Methods in molecular biology (Clifton, N.J.). 1-12. 2022
- Intratumoral heterogeneity associated with glioblastoma drug response and resistance. 185-199. 2021
- Brain Tumor Stem Cells Methods and Protocols Preface. Methods in molecular biology (Clifton, N.J.). V-V. 2019
- Detecting Stem Cell Marker Expression Using the NanoString nCounter System. Methods in molecular biology (Clifton, N.J.). 57-67. 2019
- Differentiation of Brain Tumor Initiating Cells. Methods in molecular biology (Clifton, N.J.). 85-91. 2019
- Flow Cytometric Analysis of Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 69-77. 2019
- In Vitro Assays for Screening Small Molecules. Methods in molecular biology (Clifton, N.J.). 189-196. 2019
- In Vitro Self-Renewal Assays for Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 79-84. 2019
- In Vivo Murine Models of Brain Metastasis. Methods in molecular biology (Clifton, N.J.). 231-238. 2019
- Introduction to Brain Tumor Stem Cells. Methods in molecular biology (Clifton, N.J.). 1-9. 2019
- Introduction to Cancer Stem Cells: Past, Present, and Future. Methods in molecular biology (Clifton, N.J.). 1-16. 2018
- Introduction to Cancer Stem Cells: Past, Present, and Future (vol 1692, pg 1, 2018). Methods in molecular biology (Clifton, N.J.). E1-E1. 2018
- Giant Cell Tumor. 1896-1901. 2016
- Flow cytometric identification and characterization of neural brain tumor initiating cells for pathophysiological study and biomedical applications.. 199-212. 2015
- Isolation and identification of neural cancer stem/progenitor cells.. 145-168. 2015
- Cancer stem cells in pediatric brain tumors. 2015
- Chapter 17 Flow-Cytometric Identification and Characterization of Neural Brain Tumor-Initiating Cells for Pathophysiological Study and Biomedical Applications. 199-211. 2015
- Glioblastoma Stem Cells Drive Tumor Recurrence and Patient Relapse: What's the Evidence?. 193-208. 2014
- Cancer Genomics Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2014
- Chapter 19 Brain Tumor Genomics Sequencing to Clinical Utility. 321-338. 2014
- The Brain Tumor Genome: A Comprehensive Review 2014
- Brain Tumor Genomics: Sequencing to Clinical Utility. 321-338. 2013
- Giant Cell Tumor. 1-5. 2012
- Neurosurgical management of brain tumours. 2012
- Origins of Metastasis-Initiating Cells. 229-246. 2012
- Cancer Stem Cells in Brain Cancer. 37-56. 2011
- Chapter 75 Supratentorial Low-Grade Gliomas. 572-578. 2005
- Supratentorial Low-Grade Gliomas. 572-578. 2005
-
conferences
- 249 Targeting recurrent glioblastoma with ROBO1 CAR T cells. a287-a287. 2024
- 323 Development of nuclear envelope protein-targeting CAR T cells for treatment of hyperproliferative MYC -driven group 3 medulloblastoma. a374-a374. 2024
- IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 2023
- 852 Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. Journal for ImmunoTherapy of Cancer. A891-A891. 2022
- DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. Neuro-Oncology. 98-99. 2022
- DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY. Neuro-Oncology. 291-292. 2022
- ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA. Neuro-Oncology. 228-228. 2022
- NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA.. Neuro-Oncology. 117-117. 2022
- Preclinical development of CD133 targeted immunoPET probes. Nuclear Medicine and Biology. S19-S20. 2022
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Reports. 111420-111420. 2022
- Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma. Cancer Research. 2022
- HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases. Cancer Research. 2022
- Interrogating the pre-metastastic gene signature to block brain metastases. Cancer Research. 2022
- Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer. Cancer Research. 2022
- AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 215-215. 2021
- ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. Neuro-Oncology. 175-175. 2021
- FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 22-22. 2021
- THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 21-21. 2021
- Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models.. Cancer Research. 2021
- EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. i10-i10. 2021
- EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. Neuro-Oncology. i49-i49. 2021
- PET imaging cancer stem cells using a novel zirconium-89 labelled fully human anti-CD133 antibody. Journal of Nuclear Medicine. 2021
- Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma. Cancer immunology research. PO081-PO081. 2021
- Abstract PR009: The functional genomic landscape of recurrent glioblastoma. Cancer immunology research. PR009-PR009. 2021
- Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma.. Cancer immunology research. 2021
- The functional genomic landscape of recurrent glioblastoma.. Cancer immunology research. 2021
- The functional genomic landscape of recurrent glioblastoma.. Cancer immunology research. 2021
- 5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers. Annals of Oncology. S1419-S1419. 2020
- DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 399-399. 2020
- Identification of therapy driven events on proteome landscape of patient matched primary-recurrent Glioblastoma for development of novel diagnostic and predictive biomarkers. Clinical Biochemistry. 83-83. 2020
- IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 213-213. 2020
- TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 196-196. 2020
- LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 239-239. 2019
- Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence. Cancer Research. 2019
- Abstract 3682: Therapeutic targeting of stem cell self-renewal in childhood medulloblastoma: Strategies for blocking recurrence. Cancer Research. 3682-3682. 2019
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Cancer Research. 570-570. 2019
- Abstract 570: A glioblastoma translational pipeline: discovery of novel tumor antigens that drive GBM recurrence. Immunology. 570-570. 2019
- MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE. Neuro-Oncology. ii105-ii105. 2019
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 108-108. 2019
- MUSAShi-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 112-112. 2019
- SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 117-117. 2019
- BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. 1702-1716. 2019
- A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 107-107. 2018
- DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 273-273. 2018
- MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 208-208. 2018
- Abstract 1140: Genes preserving stem cell state in group 3 medulloblastoma brain tumor initiating cells contribute to therapy evasion and relapse. Cancer Research. 1140-1140. 2018
- Abstract 148: Canonical Wnt activation as a therapeutic strategy in pediatric medulloblastoma. Cancer Research. 148-148. 2018
- Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies. Cancer Research. 1763-1763. 2018
- Abstract 1911: Uncovering novel targets of recurrent glioblastoma using transcriptomic profiling in a patient-derived xenograft model. Cancer Research. 1911-1911. 2018
- Abstract 390: Genome-wide CRISPR screens in brain tumor initiating cells (BTICs) identify potent sensitizers and resistors of conventional chemoradiotherapy. Cancer Research. 390-390. 2018
- Abstract 44: Characterization and targeting of a temporal micro-metastatic signature in human brain metastases. Cancer Research. 44-44. 2018
- INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 133-133. 2018
- SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 119-119. 2018
- Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma. Journal of Clinical Oncology. 2018
- A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 54-54. 2017
- A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 72-72. 2017
- CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 229-229. 2017
- CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 255-255. 2017
- CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 230-230. 2017
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 255-255. 2017
- GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 234-235. 2017
- IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 254-254. 2017
- PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 49-49. 2017
- PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 46-46. 2017
- THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 113-113. 2017
- Abstract 3639: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in human glioblastoma. Cancer Research. 3639-3639. 2017
- Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma. Cancer Research. 3758-3758. 2017
- Abstract 3844: Identification and validation of novel therapeutic targets driving clonal heterogeneity in treatment-refractory GBM. Cancer Research. 3844-3844. 2017
- Abstract 3870: Clonal evolution of medulloblastoma BTICs in response to therapy. Cancer Research. 3870-3870. 2017
- Abstract 5831: Activated Wnt signaling for the treatment of recurrent medulloblastoma. Cancer Research. 5831-5831. 2017
- CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 58-58. 2017
- GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 44-44. 2017
- INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI, IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 43-43. 2017
- Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis. Pancreas. 446-446. 2017
- Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Cancer immunology research. B079-B079. 2016
- Abstract B092: Therapeutic targeting of tumorigenic EphA2+/EphA3+ brain tumor initiating cells with bi-specific antibody in glioblastoma. Cancer immunology research. B092-B092. 2016
- CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 214-215. 2016
- CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 214-214. 2016
- DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. Neuro-Oncology. 211-212. 2016
- Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. Neuro-Oncology. 207-207. 2016
- THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 98-98. 2016
- Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells. Cancer Research. 1481-1481. 2016
- Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors. Cancer Research. 2300-2300. 2016
- Abstract 2512: Bmi1 identifies treatment-refractory stem cells in human glioblastoma. Cancer Research. 2512-2512. 2016
- Abstract 2680: Development and application of a novel model of human lung-to-brain metastasis: identification of TWIST2 and SPOCK1 as unique regulators of brain metastases. Cancer Research. 2680-2680. 2016
- A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS. Neuro-Oncology. 149-149. 2016
- ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 101-101. 2016
- DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. Neuro-Oncology. 40-40. 2016
- IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?. Neuro-Oncology. 150-150. 2016
- MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. Neuro-Oncology. 16-16. 2016
- Activated Wnt signaling for the therapeutic targeting of treatment-refractory medulloblastoma stem cells. Journal of Neurosurgery. A1153-A1153. 2016
- Bmi1 is a Therapeutic Target in Recurrent Medulloblastoma. Journal of Neurosurgery. A1204-A1205. 2016
- EARLY POST-OPERATIVE MRI FOLLOWING A RESECTION OF A PEDIATRIC BRAIN TUMOR - WHAT IS THE RIGHT TIMEPOINT?. Pediatric Blood and Cancer. S283-S283. 2015
- RADIATION NECROSIS IN CHILDREN - AN UNDERREPORTED PROBLEM?!. Pediatric Blood and Cancer. S282-S283. 2015
- ACTIVATED Wnt SIGNALING TARGETS Sox2+TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 23-23. 2015
- DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22-22. 2015
- An Open Label Randomized Control Pilot Study Examining the Use of Ibuprofen and Acetaminophen for Acute Headache in Post-Concussive Youth.. Journal of Head Trauma Rehabilitation. E116-E116. 2015
- RM-06 * IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. Neuro-Oncology. v187-v187. 2014
- SC-33 * POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. Neuro-Oncology. v204-v204. 2014
- GLIOMA SPECIFIC PEPTIDES: A PLATFORM FOR MOLECULAR IMAGING AND THERAPEUTIC TARGETING. Neuro-Oncology. iii37-iii37. 2014
- SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA. Neuro-Oncology. iii5-iii5. 2014
- PERSONALIZING THE TREATMENT OF PEDIATRIC MEDULLOBLASTOMA: POLO-LIKE KINASE 1 AS A MOLECULAR TARGET IN HIGH-RISK CHILDREN. Neuro-Oncology. 77-77. 2014
- Returning children and youth to activity and to school after MTBI/concussion: A conservative approach with new evidence-based guidelines. Brain Injury. 581-582. 2014
- Returning Children and Youth to Activity and to School after MTBI/Concussion: A Conservative Approach with New Evidence Based Guidelines. Journal of Head Trauma Rehabilitation. E38-E38. 2013
- Bmi1 REGULATES GLI ACETYLATION THROUGH CULLIN3 IN MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 43-43. 2013
- CLONAL EVOLUTION OF MEDULLOBLASTOMA BRAIN TUMOUR-INITIATING CELLS (BTICS) IN RESPONSE TO THERAPY: DISCOVERING THE REFRACTORY BTIC POPULATION. Neuro-Oncology. 27-27. 2013
- PERSONALIZING THE TREATMENT FOR MEDULLOBLASTOMA: POLO-LIKE KINASE 1 (PLK1) AS A MOLECULAR TARGET FOR THE SONIC HEDGEHOG (SHH) SUBTYPE. Neuro-Oncology. 2-3. 2013
- REGULATION OF MEDULLOBLASTOMA STEM CELL SELF-RENEWAL THROUGH THE DEVELOPMENTALLY CONSERVED FoxG1-Bmi1-p21 AXIS. Neuro-Oncology. 21-21. 2013
- Bmi1 AND FoxG1 REGULATE SELF-RENEWAL IN CD15+non-Shh/Wnt SUBTYPE MEDULLOBLASTOMA STEM CELLS THROUGH RECIPROCAL PROMOTER OCCUPANCY. Neuro-Oncology. 93-94. 2012
- Bmi1 REGULATION OF SONIC HEDGEHOG SIGNALING THROUGH THE E3 UBIQUITIN LIGASE CULLIN3 IN MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 94-94. 2012
- DEVELOPMENT OF IN VITRO AND IN VIVO CHEMO-AND RADIOTHERAPY MODELS FOR DETECTION OF TREATMENT-REFRACTORY MEDULLOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 94-94. 2012
- FRACTIONATED STEREOTACTIC RADIOSURGERY FOR RELAPSED PAEDIATRIC PRIMITIVE NEUROECTODERMAL TUMOURS: A SINGLE INSTITUTION EXPERIENCE. Neuro-Oncology. 146-146. 2012
- PEDIATRIC AND ADULT MEDULLOBLASTOMA: WHAT MAKES THE DIFFERENCE IN OUTCOME?. Neuro-Oncology. 86-86. 2012
- PEDIATRIC INTRACRANIAL GERMINOMA CASE SERIES: FOUR PATIENTS WITH ATYPICAL CLINICO-RADIOLOGICAL PRESENTATION. Neuro-Oncology. 54-54. 2012
- POLO-LIKE KINASE 1 (PLK1) INHIBITION KILLS GLIOBLASTOMA MULTIFORME BRAIN TUMOUR CELLS IN PART THROUGH LOSS OF SOX2 AND DELAYS TUMOUR PROGRESSION IN MICE. Neuro-Oncology. 67-67. 2012
- YB-1 BRIDGES NEURAL STEM CELLS AND BRAIN TUMOR-INITIATING CELLS VIA ITS ROLES IN DIFFERENTIATION AND CELL GROWTH. Neuro-Oncology. 14-15. 2012
- Combined Heart-Liver Transplant: An Analysis of Nearly 200 Adults Listed in the Modern Era. American Journal of Transplantation. 119-119. 2012
- Double Lung Transplant Improves Survival Compared with Single Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension.. American Journal of Transplantation. 49-49. 2012
- Modern Waitlist and Post-Transplant Survival in Combined Organ Transplant: Should Patients Listed for Heart-Kidney and Heart-Liver Transplant Be Upgraded to Status 1b at Listing?. American Journal of Transplantation. 95-95. 2012
- 128 Redo Sternotomy in Patients Undergoing Heart Transplantation: A Propensity-Matched Survival Analysis of the United Network for Organ Sharing Database. The Journal of Heart and Lung Transplantation. S52-S52. 2012
- 165 Analysis of over 1000 Patients Listed for Combined Heart-Kidney Transplant in the Modern Era. The Journal of Heart and Lung Transplantation. S64-S64. 2012
- 49 Five Years of Lung Transplantation Since the Implementation of the Lung Allocation Score: A Comparative Analysis of Patient Characteristics and Outcomes. The Journal of Heart and Lung Transplantation. S25-S26. 2012
- ROLE OF YB-1 ON GLIAL TUMORS AND ITS PROMISE AS A MOLECULAR TARGET. Neuro-Oncology. I28-I28. 2011
- TARGETING POLO-LIKE KINASE FOR THE TREATMENT OF BRAIN TUMORS AND ITS UNIQUE CAPACITY TO ELIMINATE CANCER STEM CELLS THROUGH Sox-2 INHIBITION. Neuro-Oncology. I9-I9. 2011
- Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain. Cancer Research. 2011
- Y-BOX BINDING PROTEIN-1 (YB-1) INHIBITION TRIGGERS DIFFERENTIATION OF NORMAL AND CANCER STEM CELLS FROM THE BRAIN. Neuro-Oncology. 13-13. 2011
- GLIOMATOSIS CEREBRI IN CHILDREN-A MULTIFACETED DISEASE. Pediatric Blood and Cancer. 856-857. 2010
- MANAGEMENT OF AN INTRACRANIAL MATURE TERATOMA RECURRING AS A GERMINOMA. Neuro-Oncology. II133-II133. 2010
- MEDULLOBLASTOMA OVER THREE DECADES IN A SINGLE INSTITUTION - WHAT HAVE WE ACHIEVED. Neuro-Oncology. II61-II61. 2010
- REGULATION OF BMI1 BY THE SHH PATHWAY IN HUMAN MEDULLOBLASTOMA BRAIN TUMOUR INITIATING CELLS. Neuro-Oncology. II3-II3. 2010
- PILOMYXOID ASTROCYTOMA IN TWO DIFFERENT AGE GROUPS. Neuro-Oncology. 650-650. 2009
- Identification of a cancer stem cell in human brain tumors. Neurosurgery. 487-488. 2003
-
journal articles
- ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip.. Nature Genetics. 2025
- Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.. Acta Neuropathologica. 148:74. 2024
- ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS. Neuro-Oncology. 26. 2024
- LEVERAGING GENOME-WIDE CRISPR/CAS9 KNOCKOUT DRUG SCREENS TO IDENTIFY SENSITIZERS FOR PROTEOSOME INHIBITORS IN GLIOBLASTOMA. Neuro-Oncology. 26. 2024
- MULTI-OMIC CHARACTERIZATION OF THE TEMPORAL METABOLIC ADAPTATIONS UNDERPINNING THERAPY RESISTANCE AND TUMOR RECURRENCE IN GLIOBLASTOMA. Neuro-Oncology. 26. 2024
- PYROPTOSIS IS AN ACQUIRED VULNERABILITY OF BRAIN METASTASES. Neuro-Oncology. 26. 2024
- TARGETING AXONAL GUIDANCE DEPENDENCIES IN GLIOBLASTOMA WITH ROBO1 CAR T CELLS. Neuro-Oncology. 26. 2024
- THE UROKINASE RECEPTOR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN BRAIN CANCERS. Neuro-Oncology. 26. 2024
- THERAPEUTIC TARGETING OF MISLOCALIZED NUCLEAR ENVELOPE PROTEINS INMYC-DRIVEN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 26. 2024
- De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases.. Cell Reports Medicine. 5:101755. 2024
- Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells. Nature Medicine. 30:2936-2946. 2024
- TRSC-04 DE NOVO GTP SYNTHESIS IS A METABOLIC VULNERABILITY FOR THE INTERCEPTION OF BRAIN METASTASES. NOA. 6:i40-i40. 2024
- National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection. Child's Nervous System. 40:1339-1347. 2024
- Abstract 5112: Discovery of nuclear envelope mislocalization in MYC-driven group 3 medulloblastoma. Cancer Research. 84:5112-5112. 2024
- Abstract 5238: uPAR as a novel immunotherapeutic target in recurrent glioblastoma. Cancer Research. 84:5238-5238. 2024
- Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma. Cancer Research. 84:5241-5241. 2024
- Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors. Cancer Research. 84:5846-5846. 2024
- Abstract 60: Functional mapping of glioblastoma recurrence reveals targetable dependencies in an axonal guidance pathway in highly invasive brain cancers. Cancer Research. 84:60-60. 2024
- 89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs. EJNMMI Research. 14:29. 2024
- Abstract IA004: Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies. Cancer Research. 84:IA004-IA004. 2024
- Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases. Clinical Cancer Research. 30:554-563. 2024
- Alkylating agents are possible inducers of glioblastoma and other brain tumors. Human and Experimental Toxicology. 43:9603271241256598. 2024
- P102: Systematic characterization of cancer ecosystem evolution. Genetics in Medicine Open. 2:100983-100983. 2024
- Risk factors for glioblastoma are shared by other brain tumor types. Human and Experimental Toxicology. 43:9603271241241796. 2024
- Abstract A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis. Molecular Cancer Therapeutics. 22:A109-A109. 2023
- Abstract A158: Rational development of synergistic therapies alongside BMI1 Inhibition for group 3 medulloblastoma. Molecular Cancer Therapeutics. 22:A158-A158. 2023
- Abstract C053: BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis. Molecular Cancer Therapeutics. 22:C053-C053. 2023
- Abstract C082: SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma. Molecular Cancer Therapeutics. 22:C082-C082. 2023
- Abstract C097: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Molecular Cancer Therapeutics. 22:C097-C097. 2023
- Protocol for mapping the metabolome and lipidome of medulloblastoma cells using liquid chromatography-mass spectrometry. STAR Protocols. 4:102736-102736. 2023
- EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 25:v225-v225. 2023
- Correction to: Dynamic profiling of medulloblastoma surfaceome. Acta Neuropathologica Communications. 11:169. 2023
- P02.16.B COMPENSATORY CROSS-TALK BETWEEN AUTOPHAGY AND GLYCOLYSIS REGULATES SENESCENCE AND STEMNESS IN HETEROGENEOUS GLIOBLASTOMA TUMOR SUBPOPULATIONS. Neuro-Oncology. 25:ii33-ii33. 2023
- P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. Neuro-Oncology. 25:ii49-ii49. 2023
- P10.22.B COMBINATION OF ARTS MIMETICS WITH AUTOPHAGY INHIBITORS AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME APOPTOSIS RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology. 25:ii67-ii67. 2023
- PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED POST-TRANSLATIONAL MECHANISM REGULATING THE ABUNDANCE OF THE ‘UNDRUGGABLE’ ONCOPROTEIN C-MYC IN MEDULLOBLASTOMA. Neuro-Oncology. 25:ii1-ii2. 2023
- BSBM-09 IN VIVO CRISPR ACTIVATION SCREEN IDENTIFIES ß-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) AS A DRIVER OF NON-SMALL CELL LUNG CANCER BRAIN METASTASIS. NOA. 5:iii2-iii2. 2023
- SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS. NOA. 5:iii33-iii33. 2023
- SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE. NOA. 5:iii33-iii33. 2023
- SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA. NOA. 5:iii34-iii34. 2023
- AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA. NOA. 5:i6-i6. 2023
- GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS. NOA. 5:i1-i2. 2023
- INTERCEPTING BRAIN METASTASES THROUGH METABOLIC VULNERABILITIES. NOA. 5:i2-i2. 2023
- ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER. NOA. 5:i3-i3. 2023
- UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA. NOA. 5:i10-i10. 2023
- Dynamic profiling of medulloblastoma surfaceome. Acta Neuropathologica Communications. 11:111. 2023
- Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathologica Communications. 11:110. 2023
- An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. Journal of Neuro-Oncology. 163:635-645. 2023
- Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma. Cell Reports Medicine. 4:101071-101071. 2023
- Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nature Communications. 14:2502. 2023
- A single center experience in the management of progressive juvenile pilocytic astrocytoma. Journal of Neurosurgical Sciences. 67:311-316. 2023
- Abstract 1154: Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. Cancer Research. 83:1154-1154. 2023
- Abstract 2474: Uncovering a new therapeutic vulnerability for preventing brain metastases. Cancer Research. 83:2474-2474. 2023
- Abstract 6028: Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Research. 83:6028-6028. 2023
- External ventricular drainage in the management of pediatric patients with posterior fossa tumors and hydrocephalus: a retrospective cohort study. Child's Nervous System. 39:887-894. 2023
- Comparison of Two Drainage Systems on Chronic Subdural Hematoma Recurrence. Journal of Neurological Surgery. Part A: Central European Neurosurgery. 84:157-166. 2023
- An HLA-G/SPAG9/STAT3 axis promotes brain metastases. Proceedings of the National Academy of Sciences of the United States of America. 120:e2205247120. 2023
- Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nature Communications. 14:136. 2023
- Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nature Communications. 13:7506. 2022
- Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Cell. 40:1488-1502.e7. 2022
- The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers. Acta Neuropathologica. 144:1127-1142. 2022
- 2022 Canadian Surgery Forum Sept. 15–17, 2022. Canadian Journal of Surgery. 65:s33-s111. 2022
- DDDR-03. DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. Neuro-Oncology. 24:vii98-vii99. 2022
- EPCO-07. NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA. Neuro-Oncology. 24:vii117-vii117. 2022
- EXTH-81. ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA. Neuro-Oncology. 24:vii228-vii228. 2022
- MODL-05. DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY. Neuro-Oncology. 24:vii291-vii292. 2022
- Derivation and culturing of neural stem cells from human embryonic brain tissue. STAR Protocols. 3:101628-101628. 2022
- BSCI-13 DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. NOA. 4:i3-i3. 2022
- BSCI-22 DETERMINING THE EFFECT OF NOVEL SMALL MOLECULE DRUGS AGAINST THE MIGRATION OF BRAIN METASTASIS INITIATING CELLS (BMICS). NOA. 4:i5-i5. 2022
- SYST-15 TARGETING AXONAL GUIDANCE WITH ANTI-ROBO1 CAR T CELLS: A NEW THERAPEUTIC STRATEGY FOR MALIGNANT BRAIN CANCER. NOA. 4:i24-i24. 2022
- Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures. Journal of Controlled Release. 348:386-396. 2022
- Functional discovery of targetable dependencies in recurrent glioblastoma 2022
- Abstract 3999: HLA-G, SPAG9 and STAT3 signalling: An alliance that promotes early-stage brain metastases. Cancer Research. 82:3999-3999. 2022
- Abstract 564: Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer. Cancer Research. 82:564-564. 2022
- Abstract 60: Functional mapping reveals widespread remodelling and unrecognized pathway dependencies in recurrent glioblastoma. Cancer Research. 82:60-60. 2022
- Abstract 976: Interrogating the pre-metastastic gene signature to block brain metastases. Cancer Research. 82:976-976. 2022
- Characterization of an RNA binding protein interactome reveals the targetable post-transcriptional landscape of MYC-amplified medulloblastoma 2022
- Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma. Journal of Medicinal Chemistry. 65:3193-3217. 2022
- Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?. Neuro-Oncology. 24:226-228. 2022
- Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma 2022
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. Journal for ImmunoTherapy of Cancer. 10:e003289-e003289. 2022
- Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors. Frontiers in Immunology. 13:905768. 2022
- Reoperation in adult patients with recurrent glioblastoma: A matched cohort analysis. NOA. 4:vdac115. 2022
- The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues. Frontiers in Oncology. 12:815726. 2022
- The Role of a Longitudinal, Multidisciplinary Clinic in Building a Unique Research Collaborative. Frontiers in Oncology. 12:857699. 2022
- Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. Science Advances. 7:eabi5568. 2021
- In vitro evaluation of CAR-T cells in patient-derived glioblastoma models. STAR Protocols. 2:100920-100920. 2021
- EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. Neuro-Oncology. 23:vi175-vi175. 2021
- STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 23:vi21-vi21. 2021
- STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 23:vi22-vi22. 2021
- TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 23:vi215-vi215. 2021
- TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 23:vi218-vi218. 2021
- C.5 Musashi-1 is a master regulator of aberrant translation in MYC-amplified Group 3 medulloblastoma. Canadian Journal of Neurological Sciences. 48:S19-S19. 2021
- STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. Neuro-Oncology. 23:vi21-vi21. 2021
- STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. Neuro-Oncology. 23:vi22-vi22. 2021
- TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology. 23:vi215-vi215. 2021
- TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. Neuro-Oncology. 23:vi218-vi218. 2021
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. NOA. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. NOA. 3:iii5-iii5. 2021
- BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics. Neuro-Oncology Advances. 3:iii5-iii5. 2021
- BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis. Neuro-Oncology Advances. 3:iii5-iii5. 2021
- Advances in Immunotherapy for Adult Glioblastoma. Cancers. 13:3400-3400. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. NOA. 3:ii5-ii5. 2021
- Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. Cancer Research. 81:2874-2874. 2021
- NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis. Neuro-Oncology Advances. 3:ii5-ii5. 2021
- Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma 2021
- EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 23:i10-i10. 2021
- EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. Neuro-Oncology. 23:i49-i49. 2021
- ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells. Journal of Personalized Medicine. 11:125-125. 2021
- Identification of five important genes to predict glioblastoma subtypes. NOA. 3:vdab144. 2021
- MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22:iii399-iii399. 2020
- A Patient-Derived Xenograft Model of Glioblastoma. STAR Protocols. 1:100179-100179. 2020
- Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis. STAR Protocols. 1:100124-100124. 2020
- MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 22:iii399-iii399. 2020
- Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma. STAR Protocols. 1:100174-100174. 2020
- STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 22:ii196-ii196. 2020
- TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 22:ii213-ii213. 2020
- De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology. 3:645. 2020
- STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. Neuro-Oncology. 22:ii196-ii196. 2020
- TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. Neuro-Oncology. 22:ii213-ii213. 2020
- WNT: an unexpected tumor suppressor in medulloblastoma. Molecular and Cellular Oncology. 7:1834903-1834903. 2020
- RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status. Cancers. 12:3178-3178. 2020
- Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials. 252:120105-120105. 2020
- Wnt activation as a therapeutic strategy in medulloblastoma. Nature Communications. 11:4323. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. NOA. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. NOA. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. NOA. 2:ii9-ii9. 2020
- 37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. Neuro-Oncology Advances. 2:ii6-ii7. 2020
- 39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS. Neuro-Oncology Advances. 2:ii7-ii7. 2020
- 47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES. Neuro-Oncology Advances. 2:ii9-ii9. 2020
- Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell. 181:1329-1345.e24. 2020
- The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 26:832-844.e6. 2020
- A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 39:1590-1599. 2020
- Analysis of factors that influence neurosurgical length of hospital stay among newly diagnosed pediatric brain tumor patients. Pediatric Blood and Cancer. 67:e28041. 2020
- Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. Frontiers in Immunology. 11:599253. 2020
- The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. Frontiers in Oncology. 10:603738. 2020
- Predictive measures and outcomes of extent of resection in juvenile pilocytic astrocytoma. Journal of Clinical Neuroscience. 70:79-84. 2019
- STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 21:vi239-vi239. 2019
- STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. Neuro-Oncology. 21:vi239-vi239. 2019
- Deciphering brain tumor heterogeneity, one cell at a time. Nature Medicine. 25:1474-1476. 2019
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. NOA. 1:i5-i5. 2019
- BSCI-20. THERAPEUTIC TARGETING OF HLA-G IN BRAIN METASTASES. Neuro-Oncology Advances. 1:i5-i5. 2019
- Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 572:67-73. 2019
- A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 36:51-67.e7. 2019
- Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. Journal of Neuro-Oncology. 143:417-428. 2019
- Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. Canadian Journal of Neurological Sciences. 46:403-414. 2019
- Regulation of the proline regulatory axis and autophagy modulates stemness in TP73/p73 deficient cancer stem-like cells. Autophagy. 15:934-936. 2019
- MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 21:ii108-ii108. 2019
- MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 21:ii112-ii113. 2019
- THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 21:ii117-ii117. 2019
- MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE. Neuro-Oncology. 21:ii105-ii105. 2019
- MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 21:ii108-ii108. 2019
- MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 21:ii112-ii113. 2019
- THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 21:ii117-ii117. 2019
- TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem–Like Cells in a Redox-Sensitive Manner. Clinical Cancer Research. 25:2001-2017. 2019
- Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry. 62:2651-2665. 2019
- A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations. Scientific Reports. 9:842. 2019
- EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. Methods in molecular biology (Clifton, N.J.). 1869:155-168. 2019
- Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis. World Neurosurgery. 120:e762-e775. 2018
- GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 20:vi107-vi107. 2018
- PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 20:vi208-vi208. 2018
- TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 20:vi273-vi273. 2018
- GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. Neuro-Oncology. 20:vi107-vi107. 2018
- PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. Neuro-Oncology. 20:vi208-vi208. 2018
- TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 20:vi273-vi273. 2018
- Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. Cell Death and Disease. 9:990. 2018
- Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma. Cancer Research. 78:5023-5037. 2018
- Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis. Cancer Research. 78:5124-5134. 2018
- Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology. 7:e1445459-e1445459. 2018
- MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 20:i119-i119. 2018
- MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 20:i133-i133. 2018
- Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs 2018
- 54 Genes preserving stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse. Canadian Journal of Neurological Sciences. 45:S13-S13. 2018
- MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. Neuro-Oncology. 20:i119-i119. 2018
- MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 20:i133-i133. 2018
- P.033 Biopsy versus subtotal versus gross total resection in patients with low-grade glioma: a systematic review and meta-analysis. Canadian Journal of Neurological Sciences. 45:S24-S24. 2018
- P.044 Salvage therapy in recurrent pediatric medulloblastoma: A single centre experience. Canadian Journal of Neurological Sciences. 45:S27-S27. 2018
- Preclinical studies of BMI-1 modulator PTC596 in diffuse intrinsic pontine gliomas, pediatric high-grade gliomas and medulloblastoma.. Journal of Clinical Oncology. 36:e14051-e14051. 2018
- Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. The Lancet. 391:1197-1204. 2018
- EMT: Mechanisms and therapeutic implications. Pharmacology and Therapeutics. 182:80-94. 2018
- Overweight, obesity and adiposity in survivors of childhood brain tumours: a systematic review and meta‐analysis. Clinical Obesity. 8:55-67. 2018
- Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival. Stem Cells International. 2018:1-19. 2018
- Erratum to: Introduction to Cancer Stem Cells: Past, Present, and Future. Methods in molecular biology (Clifton, N.J.). 1692:E1-E1. 2018
- Identification and Co-Targeting of EphA2/EphA3 Cancer Stem Cells in Recurrent Human Glioblastoma. SSRN Electronic Journal. 2018
- Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 553:101-105. 2018
- Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. Cell Reports. 21:2772-2784. 2017
- Evaluating overweight and obesity prevalence in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews. 6:43. 2017
- RNAi screen identifies essential regulators of human brain metastasis-initiating cells. Acta Neuropathologica. 134:923-940. 2017
- Brain tumor initiating cells: with great technology will come greater understanding. Future Neurology. 12:223-236. 2017
- CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi46-vi46. 2017
- CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi49-vi49. 2017
- CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 19:vi54-vi54. 2017
- EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 19:vi72-vi72. 2017
- IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 19:vi113-vi113. 2017
- STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 19:vi229-vi229. 2017
- STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:vi230-vi230. 2017
- STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi234-vi235. 2017
- TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19:vi254-vi254. 2017
- TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:vi255-vi255. 2017
- TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi255-vi255. 2017
- CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi46-vi46. 2017
- CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 19:vi49-vi49. 2017
- CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 19:vi54-vi54. 2017
- EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 19:vi72-vi72. 2017
- IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 19:vi113-vi113. 2017
- STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. Neuro-Oncology. 19:vi229-vi229. 2017
- STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:vi230-vi230. 2017
- STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi234-vi235. 2017
- TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19:vi254-vi254. 2017
- TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:vi255-vi255. 2017
- TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. Neuro-Oncology. 19:vi255-vi255. 2017
- Development of an Atypical Teratoid Rhabdoid Tumor in a Meningioma. International Journal of Surgical Pathology. 25:567-572. 2017
- The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. Obesity Reviews. 18:899-914. 2017
- Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology. 133:539-552. 2017
- Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Annals of Oncology. 28:1448-1456. 2017
- A.03 Analyses of surgical and MRI factors associated with cerebellar mutism. Canadian Journal of Neurological Sciences. 44:S9-S9. 2017
- MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:iv44-iv44. 2017
- TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 19:iv54-iv54. 2017
- TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:iv58-iv58. 2017
- MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. Neuro-Oncology. 19:iv44-iv44. 2017
- TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. Neuro-Oncology. 19:iv54-iv54. 2017
- TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. Neuro-Oncology. 19:iv58-iv58. 2017
- Adiposity in childhood brain tumors: A report from the Canadian Study of Determinants of Endometabolic Health in Children (CanDECIDE Study). Scientific Reports. 7:45078. 2017
- Atraumatic versus traumatic lumbar puncture needles: a systematic review and meta-analysis protocol. BMJ Open. 7:e014478-e014478. 2017
- The use of ibuprofen and acetaminophen for acute headache in the postconcussive youth: A pilot study. Paediatrics and Child Health. 22:2-6. 2017
- CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence. Oncogene. 36:606-617. 2017
- Bmi1 – A Path to Targeting Cancer Stem Cells. European Oncology and Haematology. 13:147-147. 2017
- Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. Frontiers in Oncology. 7:220. 2017
- Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. Human Pathology. 59:125-130. 2017
- The effectiveness of interventions to treat obesity in survivors of childhood brain tumors: a systematic review protocol. Systematic Reviews. 5:101. 2016
- The identification of human pituitary adenoma-initiating cells. Acta Neuropathologica Communications. 4:125. 2016
- IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. Neuro-Oncology. 18:vi98-vi98. 2016
- TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. Neuro-Oncology. 18:vi207-vi207. 2016
- TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. Neuro-Oncology. 18:vi211-vi212. 2016
- TMOD-37. CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. Neuro-Oncology. 18:vi214-vi215. 2016
- Modelling Therapy Resistance for the Identification of Treatment-Refractory Cell Population(s) in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S1-S1. 2016
- OS2 - 166 A Novel Model of Human Lung-to-Brain Metastasis and its Application to the Identification of Essential Metastatic Regulatory Genes. Canadian Journal of Neurological Sciences. 43:S2-S2. 2016
- OS4 - 161 Activated Wnt Signaling for the Therapeutic Targeting of Treatment-Refractory Medulloblastoma Stem Cells. Canadian Journal of Neurological Sciences. 43:S2-S3. 2016
- PS1 - 169 Discovering the Treatment Refractory BTIC Population in Group 3 Medulloblastoma through Therapy Adapted Patient-Derived Human Mouse Xenograft (PDX) Model. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS1 - 170 Bmi1 is a Therapeutic Target in Recurrent Childhood Medulloblastoma. Canadian Journal of Neurological Sciences. 43:S10-S10. 2016
- PS2 - 171 Bmi1 Identifies Treatment-Refractory Stem Cells in Human Glioblastoma. Canadian Journal of Neurological Sciences. 43:S13-S13. 2016
- PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells. Canadian Journal of Neurological Sciences. 43:S13-S14. 2016
- Subdural Hematoma Mimickers: A Systematic Review. World Neurosurgery. 93:73-80. 2016
- Abstract 2475: Bmi1 is a therapeutic target in recurrent medulloblastoma. Cancer Research. 76:2475-2475. 2016
- CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. Neuro-Oncology. 18:iii16.2-iii16. 2016
- EPI-04DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. Neuro-Oncology. 18:iii40.3-iii40. 2016
- MB-22ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 18:iii101.3-iii101. 2016
- QOS-21A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS. Neuro-Oncology. 18:iii149.4-iii149. 2016
- QOS-22IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?. Neuro-Oncology. 18:iii150.1-iii150. 2016
- Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. Neuro-Oncology. 18:350-360. 2016
- A novel stem cell culture model of recurrent glioblastoma. Journal of Neuro-Oncology. 126:57-67. 2016
- Development of a Patient-Derived Xenograft Model Using Brain Tumor Stem Cell Systems to Study Cancer. Methods in molecular biology (Clifton, N.J.). 1458:231-245. 2016
- Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor–Initiating Cells. Clinical Cancer Research. 21:5324-5337. 2015
- Reply to Letter. Annals of Surgery. 262:e114-e115. 2015
- Endovascular Thrombectomy for Acute Ischemic Stroke. Journal of the American Medical Association (JAMA). 314:1832-1832. 2015
- ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 17:v38.4-v39. 2015
- ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 17:v38-v39. 2015
- BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. Neuro-Oncology. 17:v51.5-v52. 2015
- BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. Neuro-Oncology. 17:v51-v52. 2015
- STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. Neuro-Oncology. 17:v213.1-v213. 2015
- STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 6:27461-27477. 2015
- Exploring predictors of surgery and comparing operative treatment approaches for pediatric intracranial arachnoid cysts: a case series of 83 patients. Journal of Neurosurgery: Pediatrics. 16:275-282. 2015
- Letter to the Editor: Temporal evolution of medulloblastoma subgroups. Journal of Neurosurgery: Pediatrics. 16:349-351. 2015
- Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 34:3.3.1-3.3.13. 2015
- A Balanced Protocol for Return to School for Children and Youth Following Concussive Injury. Clinical Pediatrics. 54:783-792. 2015
- Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro-Oncology. 17:868-881. 2015
- MB-14 * DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology. 17:iii22-iii22. 2015
- MB-15 * ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 17:iii23-iii23. 2015
- MB-15ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. Neuro-Oncology. 17:iii23-iii23. 2015
- Cervical Spine Clearance in Obtunded Patients After Blunt Traumatic Injury. ACP journal club. 162:429-437. 2015
- Development of a Conservative Protocol to Return Children and Youth to Activity Following Concussive Injury. Clinical Pediatrics. 54:152-163. 2015
- MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. Stem Cells International. 2015:1-15. 2015
- The role of stem cells in pediatric central nervous system malignancies.. Advances in Experimental Medicine and Biology. 853:49-68. 2015
- Revealed: The spy who regulates neuroblastoma stem cells. Oncotarget. 5:11014-11016. 2014
- RM-06IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. Neuro-Oncology. 16:v187-v187. 2014
- SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. Neuro-Oncology. 16:v204-v204. 2014
- MEDULLOBLASTOMA. Neuro-Oncology. 16:i71-i96. 2014
- Brain Metastasis-Initiating Cells: Survival of the Fittest. International Journal of Molecular Sciences. 15:9117-9133. 2014
- Chronic Subdural Hematoma Management. Annals of Surgery. 259:449-457. 2014
- Generation of Murine Xenograft Models of Brain Tumors from Primary Human Tissue for In Vivo Analysis of the Brain Tumor-Initiating Cell. Methods in molecular biology (Clifton, N.J.). 1210:37-49. 2014
- Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. Cancer Research. 73:6734-6744. 2013
- Conflicting Diagnosis of Dermal Sinus Tract and Tethered Cord. Canadian Journal of Neurological Sciences. 40:889-891. 2013
- Is low-level laser therapy in relieving neck pain effective? Systematic review and meta-analysis. Rheumatology International. 33:2493-2501. 2013
- Medulloblastoma stem cells: Modeling tumor heterogeneity. Cancer Letters. 338:23-31. 2013
- FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells. Stem Cells. 31:1266-1277. 2013
- Expressional Analysis of GFP-Tagged Cells in an In Vivo Mouse Model of Giant Cell Tumor of Bone. Open Orthopaedics Journal. 7:109-113. 2013
- A Cancer Stem Cell Model for Studying Brain Metastases From Primary Lung Cancer. Journal of the National Cancer Institute. 105:551-562. 2013
- Evolution of Brain Tumor-Initiating Cell Research: In Pursuit of A Moving Target. Future Neurology. 8:1-3. 2013
- Investigating the Link between Molecular Subtypes of Glioblastoma, Epithelial-Mesenchymal Transition, and CD133 Cell Surface Protein. PLoS ONE. 8:e64169-e64169. 2013
- Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting. Journal of Visualized Experiments. 4111. 2012
- GBM secretome induces transient transformation of human neural precursor cells. Journal of Neuro-Oncology. 109:457-466. 2012
- Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells. 30:1064-1075. 2012
- Medulloblastoma stem cells: where development and cancer cross pathways. Pediatric Research. 71:516-522. 2012
- Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. Stem Cell Research. 8:141-153. 2012
- Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 31:187-199. 2012
- Abstracts from the 2011 BNOS Conference, June 29 – July 1, 2011, Homerton College, Cambridge. Neuro-Oncology. 13:ii1-ii14. 2011
- Combined Staged Endoscopic and Microsurgical Approach of a Third Ventricular Choroid Plexus Papilloma in an Infant. Minimally Invasive Neurosurgery. 54:264-267. 2011
- Endoscopic transnasal drainage of frontal epidural abscesses.. Journal of Otolaryngology - Head and Neck Surgery. 40:401-406. 2011
- YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research. 71:5569-5578. 2011
- Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. Journal of Trauma and Acute Care Surgery. 70:873-884. 2011
- Culture and Isolation of Brain Tumor Initiating Cells. Current Protocols in Stem Cell Biology. 11:Unit3.3. 2009
- From Birth Till Death: Neurogenesis, Cell Cycle, and Neurodegeneration. Anatomical Record. 292:1953-1961. 2009
- Characterization of brain cancer stem cells: a mathematical approach. Cell Proliferation. 42:529-540. 2009
- An unexpected intracranial pressure crisis: infant brain abscess of unusual aetiology. Child's Nervous System. 25:377-381. 2009
- Brain Tumor Stem Cells: Identification and Concepts. Neurosurgery Clinics of North America. 18:31-38. 2007
- Identification of human brain tumour initiating cells. Nature. 432:396-401. 2004
- Cancer stem cells in nervous system tumors. Oncogene. 23:7267-7273. 2004
- Identification of a cancer stem cell in human brain tumors.. Cancer Research. 63:5821-5828. 2003
- Occipitocervical reconstruction with the Ohio Medical Instruments Loop: results of a multicenter evaluation in 30 cases. Journal of Neurosurgery. 98:239-246. 2003
- Cerebral salt wasting: Truths, fallacies, theories, and challenges. Critical Care Medicine. 30:2575-2579. 2002
- A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting. Journal of Neurosurgery. 95:420-424. 2001
- 807 Occipitocervical Reconstruction with the OMI Loop: Results of a Multicenter Trial in 50 Cases with Independent Review. Neurosurgery. 49:538-538. 2001
- 807 Occipitocervical Reconstruction with the OMI Loop: Results of a Multicenter Trial in 50 Cases with Independent Review. Neurosurgery. 49:538-538. 2001
- Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting. Journal of Visualized Experiments.
-
preprints